The Effects of HIV Tat DNA on Regulating the Immune Response of HIV DNA Vaccine in Mice

Overview

Journal Virol J

Publisher Biomed Central

Specialty Microbiology

Date 2013 Oct 1

PMID 24073803

Citations 5

Authors

Ye Liu

Fusheng Li

Zhi Qi

Yanling Hao

Kunxue Hong

Yong Liu

Yulong Cong

Yiming Shao

Affiliations

Soon will be listed here.

Abstract

Background: HIV trans-activator protein (Tat) is the crucial factor to control HIV transcription, and is usually considered as an important immunogen for the design of HIV vaccine. Recent studies reported some special bio-activities of Tat protein on immunoregulation. However, to date, few studies have focused on exploring the effects of Tat expression plasmid (pTat) on regulating the immune responses induced by HIV DNA vaccines. In this study, our main objective is to investigate the immunoregulation mediated by pTat in mice.

Methods: Four gene-coding plasmids (pTat, pGag, pEnv and pPol) were constructed, and the gene expression was detected by western blot method. The effects of pTat on regulating the immune responses to antigens Gag, Env, Pol were assessed by enzyme-linked immunospot and enzyme-linked immunosorbent assay. The data was analysed by one-way analysis of variance.

Results: After two immunizations, mice vaccinated with antigen expressing plasmid (pGag, pEnv or pPol) plus pTat exhibited significantly stronger IFN-gamma response than that vaccinated with the corresponding antigen alone. Moreover, mice receiving two injections of antigen plus pTat exhibited the same strong IFN-gamma response as those receiving three injections of antigen alone did. Furthermore, addition of pTat not only induced a more balanced Th1 and Th2 response, but also broadened IgG subclass responses to antigens Gag and Pol.

Conclusion: pTat exhibited the appreciable effects on modulating immune responses to HIV antigens Gag, Env and Pol, providing us interesting clues on how to optimize HIV DNA vaccine.

Citing Articles

Nanoparticle containing recombinant excretory/secretory-24 protein of enhanced the cellular immune responses in mice.

Hasan M, Haseeb M, Gadahi J, Ehsan M, Wang Q, Lakho S Front Vet Sci. 2024; 11:1470084.

PMID: 39600880 PMC: 11588750. DOI: 10.3389/fvets.2024.1470084.

Heterologous DNA Prime/Protein Boost Immunization Targeting Nef-Tat Fusion Antigen Induces Potent T-cell Activity and Anti-SCR HIV-1 Effects.

Sadeghi L, Bolhassani A, Mohit E, Baesi K, Aghasadeghi M Curr HIV Res. 2024; 22(2):109-119.

PMID: 38712371 DOI: 10.2174/011570162X297602240430142231.

Two dimensional nanosheets as immunoregulator improve HIV vaccine efficacy.

Liu Y, Balachandran Y, Li Z, Cong Y, Shao Y, Jiang X Chem Sci. 2022; 13(1):178-187.

PMID: 35059165 PMC: 8694375. DOI: 10.1039/d1sc04044h.

Subcutaneous administration CpG-ODNs acts as a potent adjuvant for an HIV-1-tat-based vaccine candidate to elicit cellular immunity in BALB/c mice.

Panahi Z, Abdoli A, Mosayebi G, Mahdavi M, Bahrami F Biotechnol Lett. 2018; 40(3):527-533.

PMID: 29313255 DOI: 10.1007/s10529-017-2497-9.

Tat-induced histopathological alterations mediate hippocampus-associated behavioural impairments in rats.

Harricharan R, Thaver V, Russell V, Daniels W Behav Brain Funct. 2015; 11:3.

PMID: 25880773 PMC: 4333156. DOI: 10.1186/s12993-014-0047-3.

References

Tsen S, Paik A, Hung C, Wu T . Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells. Expert Rev Vaccines. 2007; 6(2):227-39. PMC: 3190226. DOI: 10.1586/14760584.6.2.227. View

Turbant S, Martinon F, Moine G, Le Grand R, Leonetti M . Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice. Vaccine. 2009; 27(39):5349-56. DOI: 10.1016/j.vaccine.2009.06.083. View

Gurunathan S, Klinman D, Seder R . DNA vaccines: immunology, application, and optimization*. Annu Rev Immunol. 2000; 18:927-74. DOI: 10.1146/annurev.immunol.18.1.927. View

Gupta S, Boppana R, Mishra G, Saha B, Mitra D . HIV-1 Tat suppresses gp120-specific T cell response in IL-10-dependent manner. J Immunol. 2007; 180(1):79-88. DOI: 10.4049/jimmunol.180.1.79. View

Vasan S, Schlesinger S, Huang Y, Hurley A, Lombardo A, Chen Z . Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One. 2010; 5(1):e8617. PMC: 2799527. DOI: 10.1371/journal.pone.0008617. View

Barillari G, Gendelman R, Gallo R, Ensoli B . The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci U S A. 1993; 90(17):7941-5. PMC: 47263. DOI: 10.1073/pnas.90.17.7941. View

Tsang C, Babiuk S, van Drunen Littel-van den Hurk S, Babiuk L, Griebel P . A single DNA immunization in combination with electroporation prolongs the primary immune response and maintains immune memory for six months. Vaccine. 2007; 25(30):5485-94. DOI: 10.1016/j.vaccine.2007.03.009. View

Gordon S . Alternative activation of macrophages. Nat Rev Immunol. 2003; 3(1):23-35. DOI: 10.1038/nri978. View

Fanales-Belasio E, Moretti S, Fiorelli V, Tripiciano A, Cossut M, Scoglio A . HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection. J Immunol. 2009; 182(5):2888-97. DOI: 10.4049/jimmunol.0711406. View

10.

Kittiworakarn J, Lecoq A, Moine G, Thai R, Lajeunesse E, Drevet P . HIV-1 Tat raises an adjuvant-free humoral immune response controlled by its core region and its ability to form cysteine-mediated oligomers. J Biol Chem. 2005; 281(6):3105-15. DOI: 10.1074/jbc.M509899200. View

11.

Ensoli B, Fiorelli V, Ensoli F, Cafaro A, Titti F, Butto S . Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS. 2006; 20(18):2245-61. DOI: 10.1097/QAD.0b013e3280112cd1. View

12.

Gallo R, Ensoli B . Regulation of Cellular Gene Expression and Function by the Human Immunodeficiency Virus Type 1 Tat Protein. J Biomed Sci. 1995; 2(3):189-202. DOI: 10.1007/BF02253380. View

13.

Malm M, Sikut R, Krohn K, Blazevic V . GTU-MultiHIV DNA vaccine results in protection in a novel P815 tumor challenge model. Vaccine. 2007; 25(17):3293-301. DOI: 10.1016/j.vaccine.2007.01.003. View

14.

Dolter K, Evans C, Ellefsen B, Song J, Boente-Carrera M, Vittorino R . Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation. Vaccine. 2010; 29(4):795-803. DOI: 10.1016/j.vaccine.2010.11.011. View

15.

Banerjee K, Klasse P, Sanders R, Pereyra F, Michael E, Lu M . IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res Hum Retroviruses. 2010; 26(4):445-58. PMC: 2864049. DOI: 10.1089/aid.2009.0223. View

16.

Novitsky V, Rybak N, McLane M, Gilbert P, Chigwedere P, Klein I . Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design. J Virol. 2001; 75(19):9210-28. PMC: 114489. DOI: 10.1128/JVI.75.19.9210-9228.2001. View

17.

Andre F . Vaccinology: past achievements, present roadblocks and future promises. Vaccine. 2003; 21(7-8):593-5. DOI: 10.1016/s0264-410x(02)00702-8. View

18.

Kubota E, McKenzie D, Dutton R, Swain S . Role of T cells in the B-cell response: glutaraldehyde-fixed T-helper hybridoma cells synergize with the lymphokine IL-4 to induce B-cell activation and proliferation. Immunology. 1991; 72(1):40-7. PMC: 1384333. View

19.

Faurez F, Dory D, Le Moigne V, Gravier R, Jestin A . Biosafety of DNA vaccines: New generation of DNA vectors and current knowledge on the fate of plasmids after injection. Vaccine. 2010; 28(23):3888-95. DOI: 10.1016/j.vaccine.2010.03.040. View

20.

Wolff J, Malone R, Williams P, Chong W, Acsadi G, Jani A . Direct gene transfer into mouse muscle in vivo. Science. 1990; 247(4949 Pt 1):1465-8. DOI: 10.1126/science.1690918. View